| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Enhanced Group Inc.
13D/A
Amendment 4
ENHA · 29333R107
|
34.3% |
9/21/2026
Event 9/17/2026
|
|||
| Apeiron Investment Group Ltd. | 34.3% | ||||
| Enhanced Holdings LP | 34.3% | ||||
| Enhanced Holdings GP | 34.3% | ||||
| Christian Angermayer | 34.3% | ||||
|
AtaiBeckley Inc.
13D/A
Amendment 5
ATAI · 04650F101
|
0% |
9/14/2026
Event 9/11/2026
|
|||
| Apeiron Investment Group Ltd. | 0% | ||||
| Apeiron Presight Capital Fund II, L.P. | 0% | ||||
| Presight Capital Management I, L.L.C. | 0% | ||||
| Fabian Hansen | 0% | ||||
| Christian Angermayer | 0% | ||||
|
Enhanced Group Inc.
13D/A
Amendment 3
ENHA · 29333R107
|
31.5% |
8/20/2026
Event 8/14/2026
|
|||
| Apeiron Investment Group Ltd. | 31.5% | ||||
| Enhanced Holdings LP | 31.5% | ||||
| Enhanced Holdings GP | 31.5% | ||||
| Christian Angermayer | 31.5% | ||||
|
Enhanced Group Inc.
13D/A
Amendment 2
ENHA · 29333R107
|
26.6% |
7/24/2026
Event 7/22/2026
|
|||
| Apeiron Investment Group Ltd. | 26.6% | ||||
| Enhanced Holdings LP | 26.6% | ||||
| Enhanced Holdings GP | 26.6% | ||||
| Christian Angermayer | 26.6% | ||||
|
AtaiBeckley Inc.
13D/A
Amendment 4
ATAI · 04650F101
|
15.4% |
7/17/2026
Event 7/15/2026
|
|||
| Apeiron Investment Group Ltd. | 15.1% | ||||
| Apeiron Presight Capital Fund II, L.P. | 0.5% | ||||
| Presight Capital Management I, L.L.C. | 0.5% | ||||
| Fabian Hansen | 0.5% | ||||
| Christian Angermayer | 15.4% | ||||
|
Enhanced Group Inc.
13D/A
Amendment 1
ENHA · 29333R107
|
24.4% |
6/16/2026
Event 6/14/2026
|
|||
| Apeiron Investment Group Ltd. | 24.4% | ||||
| Enhanced Holdings LP | 24.4% | ||||
| Enhanced Holdings GP | 24.4% | ||||
| Christian Angermayer | 24.4% | ||||
|
Enhanced Group Inc.
13D
ENHA · 29333R107
|
24.4% |
5/14/2026
Event 5/7/2026
|
|||
| Apeiron Investment Group Ltd. | 24.4% | ||||
| Enhanced Holdings LP | 24.4% | ||||
| Enhanced Holdings GP | 24.4% | ||||
| Christian Angermayer | 24.4% | ||||
|
ATAI Life Sciences N.V.
13D/A
Amendment 3
IGXT · 45822R101
|
24.0% |
10/20/2025
Event 10/16/2025
|
|||
| Apeiron Investment Group Ltd. | 23.4% | ||||
| Apeiron Presight Capital Fund II, L.P. | 0.8% | ||||
| Presight Capital Management I, L.L.C. | 0.8% | ||||
| Fabian Hansen | 0.8% | ||||
| Christian Angermayer | 24.0% | ||||
|
ATAI Life Sciences N.V.
13D/A
Amendment 2
IGXT · 45822R101
|
24.3% |
8/18/2025
Event 8/14/2025
|
|||
| Apeiron Investment Group Ltd. | 23.7% | ||||
| Apeiron Presight Capital Fund II, L.P. | 0.8% | ||||
| Presight Capital Management I, L.L.C. | 0.8% | ||||
| Fabian Hansen | 0.8% | ||||
| Christian Angermayer | 24.3% | ||||
|
ATAI Life Sciences N.V.
13D/A
Amendment 1
IGXT · 45822R101
|
22.2% |
6/4/2025
Event 6/2/2025
|
|||
| Apeiron Investment Group Ltd. | 22.1% | ||||
| Apeiron Presight Capital Fund II, L.P. | 0.9% | ||||
| Presight Capital Management I, L.L.C. | 0.9% | ||||
| Fabian Hansen | 0.9% | ||||
| Christian Angermayer | 22.2% | ||||
|
ATAI Life Sciences N.V.
13D
IGXT · 45822R101
|
22.7% |
2/24/2025
Event 2/14/2025
|
|||
| Apeiron Investment Group Ltd. | 22.6% | ||||
| Apeiron Presight Capital Fund II, L.P. | 0.9% | ||||
| Presight Capital Management I, L.L.C. | 0.9% | ||||
| Fabian Hansen | 0.9% | ||||
| Christian Angermayer | 22.7% | ||||
|
Neuphoria Therapeutics Inc.
13D/A
Amendment 2
NEUP · 64136E102
|
4.5% |
1/28/2025
Event 1/24/2025
|
|||
| Apeiron Investment Group Ltd. | 4.5% | ||||
| Apeiron Presight Capital Fund II, L.P. | 0% | ||||
| Presight Capital Management I, L.L.C. | 0% | ||||
| Fabian Hansen | 0% | ||||
| Christian Angermayer | 4.5% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.